financetom
Business
financetom
/
Business
/
US sues Norfolk Southern to stop delays on Amtrak passenger route
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
US sues Norfolk Southern to stop delays on Amtrak passenger route
Jul 30, 2024 9:57 AM

WASHINGTON (Reuters) - The U.S. Justice Department filed a civil suit on Tuesday against Norfolk Southern ( NSC ) alleging that the transport company is delaying passenger trains on Amtrak's Crescent Route between New York City and New Orleans in violation of federal law.

Norfolk did not immediately respond to a request for comment.

The Biden administration has made boosting passenger rail service and high-speed rail project a top priority. Congress approved $66 billion in funding for rail projects as part of a massive infrastructure bill in 2021, with $22 billion dedicated to Amtrak and $36 billion made available for grants.

Amtrak wants to break even and double total ridership to 66 million by 2040. Its passenger numbers grew 45% from 2003 to 2019 to 32.3 million.

Amtrak said last year that half of the 46 states it serves have minimal service. Florida, Ohio and Arizona, the Mountain West and Gulf Coast are served by long distance trains that provide no more than one round trip a day.

The 1,377-mile passenger line stops at 33 towns and cities and Norfolk Southern ( NSC ) controls 1,140 miles of rail line on the Crescent Route and handles dispatching for all trains along that segment, including freight trains it operates.

The Justice Department said 266,000 passengers traveled on the Crescent Route last year and only 24% of southbound Crescent Route passenger trains traveling on Norfolk Southern ( NSC )-controlled track arrived at their destination on time.

Federal law requires Norfolk Southern ( NSC ) to give Amtrak passenger trains preference over freight trains but the Justice Department said Norfolk Southern ( NSC ) regularly fails to do so, "leading to widespread delays that harm and inconvenience train passengers, negatively affect Amtrak's financial performance, and impede passenger rail transportation."

"Americans should not experience travel delays because rail carriers break the law," said Attorney General Merrick Garland.

Transportation Secretary Pete Buttigieg said "for half a century, federal law has required freight rail companies to give Amtrak passenger rail service preference on their tracks - yet compliance with this important law has been uneven at best."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Healthcare REIT LTC Q3 revenue beats expectations, helped by SHOP expansion 
Healthcare REIT LTC Q3 revenue beats expectations, helped by SHOP expansion 
Nov 4, 2025
Overview * LTC Q3 2025 revenue grows significantly, beating analyst expectations * Company reports Q3 net loss due to non-cash write-offs and increased expenses * LTC raises full-year guidance, driven by acquisitions and SHOP outperformance Outlook * Company raises full-year 2025 EPS guidance to $2.45-$2.47 * LTC expects Q4 2025 Core FFO per share of $0.67-$0.69 * Company anticipates closing...
AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales
AnaptysBio Q3 collaboration revenue jumps on GSK's Jemperli sales
Nov 4, 2025
Overview * AnaptysBio ( ANAB ) Q3 collaboration revenue rises significantly due to GSK milestone achievements * Company plans to separate biopharma operations from royalty assets by YE 2026 * AnaptysBio ( ANAB ) reports Q3 net income, contrasting with a loss in the prior year Outlook * AnaptysBio ( ANAB ) plans to separate biopharma operations from royalty assets...
Flavors and fragrances maker IFF's Q3 sales beat estimates
Flavors and fragrances maker IFF's Q3 sales beat estimates
Nov 4, 2025
Overview * IFF Q3 sales decline 8% yr/yr but beat analyst expectations * Company reaffirms full-year 2025 financial guidance despite challenging environment Outlook * IFF maintains full-year 2025 sales guidance of $10.6 bln to $10.9 bln * IFF expects 2025 adjusted operating EBITDA of $2 bln to $2.15 bln * IFF anticipates 1%-4% comparable currency neutral sales growth, lower end...
PTC Therapeutics Q3 Swings to Profit, Revenue Rises
PTC Therapeutics Q3 Swings to Profit, Revenue Rises
Nov 4, 2025
05:07 PM EST, 11/04/2025 (MT Newswires) -- PTC Therapeutics ( PTCT ) reported Q3 earnings late Tuesday of $0.20 per diluted share, swinging from a loss of $1.39 a year earlier. Analysts polled by FactSet expected a loss of $1.13. Revenue for the three months ended Sept. 30 was $211 million, up from $196.8 million a year earlier. Analysts surveyed...
Copyright 2023-2026 - www.financetom.com All Rights Reserved